VivoSim Labs, Inc. (NASDAQ:VIVS) Sees Large Drop in Short Interest
by Amy Steele · The Cerbat GemVivoSim Labs, Inc. (NASDAQ:VIVS – Get Free Report) was the target of a large decline in short interest in the month of January. As of January 15th, there was short interest totaling 8,396 shares, a decline of 24.4% from the December 31st total of 11,105 shares. Currently, 0.3% of the shares of the company are short sold. Based on an average daily trading volume, of 42,227 shares, the short-interest ratio is presently 0.2 days. Based on an average daily trading volume, of 42,227 shares, the short-interest ratio is presently 0.2 days. Currently, 0.3% of the shares of the company are short sold.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VivoSim Labs in a research report on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.
Institutional Trading of VivoSim Labs
A hedge fund recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP acquired a new stake in shares of VivoSim Labs, Inc. (NASDAQ:VIVS – Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned approximately 0.89% of VivoSim Labs at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.23% of the company’s stock.
VivoSim Labs Stock Up 71.8%
Shares of NASDAQ:VIVS opened at $2.92 on Monday. VivoSim Labs has a 12-month low of $1.41 and a 12-month high of $21.96. The company’s 50 day moving average price is $2.06 and its two-hundred day moving average price is $2.36. The firm has a market cap of $7.62 million, a PE ratio of -0.66 and a beta of 1.21.
VivoSim Labs (NASDAQ:VIVS – Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.98) earnings per share (EPS) for the quarter. The company had revenue of $0.03 million during the quarter. VivoSim Labs had a negative net margin of 1,413.57% and a negative return on equity of 28.83%.
About VivoSim Labs
VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.
The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.